Animal health in 2017: A year when antibiotic alternatives were pushed into the spotlight
There have been many changes across the animal health sector in 2017 both in terms of new legislation and industry consolidation. Download the full report below.
Change was afoot literally from day one. Long-awaited guidelines were officially implemented by the US FDA on the first working day of the year, marking a milestone in the nation’s campaign against antimicrobial resistance (AMR) in food animals.
The Guidance for Industry #213 (GFI #213) was first published by the FDA in 2013 to bring antimicrobial drugs with importance in human medicine under veterinary oversight. The new policies also aim to eliminate the use of antimicrobials in animals for growth promotion purposes.
As of January 3, 2017, all affected veterinary drug applications had either aligned with the recommendations outlined in GFI #213 or their approvals had been voluntarily withdrawn.
Many companies in the animal health industry have been very vocal about this period of transition as sales of non- medically important antimicrobials decline.
While markets such as Europe have been dealing with this trend for longer, the reality of the waning influence of antimicrobials in the US hit home in 2017.
Much like in the companion animal segment, the food-producing animal portion of the industry is now seeing innovation from both multinationals and start-ups. The need for antimicrobial alternatives has stirred R&D departments
“We are at a transformational moment in our industry in the sense of how animals are being produced and how customers expect them to be produced” across the globe and seen a whole of firms focus more time of developing solutions in the animal health and nutrition such as Cargill, Evonik Industries and Royal DSM, to name a few.
Download the full 2017 review report below.